Warwick spin-out company, Recycling Technologies, explains to The Telegraph how its recycling processes could help tackle the world's waste plastic mountains.
The company's new plant, opened in Swindon, Wiltshire, uses a technique called pyrolysis, which "cracks" plastic into more basic molecules to form an oil called Plaxx, which can then be used as a fuel, or to make new plastic. Operators say the new plant will be able to process the plastic of the entire town
The company has also recently released a new video explaining how the pyrolysis process works.
Transfer of Warwick Ventures Limiteds activities to the University of Warwick
The University has approved the transfer of the existing activities of Warwick Ventures Limited, the wholly-owned subsidiary company of the University, to Warwick Ventures as a department of the University.
This is a change of corporate structure only and the research translation services that Warwick Ventures provides to academic Departments will not change as a result of this transfer.
As currently for the subsidiary, Warwick Ventures will operate within the Knowledge Group, comprising the Library and Research & Impact Services. This change is planned to facilitate stronger and seamless Impact support services by enabling closer working between the three.
The move demonstrates the University’s continuing strong commitment to technology transfer and Warwick Ventures as means of delivering economic and social Impact from its world-renowned research.
New software that can track how biological cells respond to chemical signals and change their shape is being offered free to academic researchers.
Called QuimP, the software is useful in many areas of life sciences research, including screening for novel drugs, discrimination between healthy and malignant cells, and basic research into how cells of our immune system migrate, for example.
It was developed at the University of Warwick’s Department of Computer Science, by Dr Till Bretschneider and has been licensed for academic use by Warwick Ventures, the University’s technology transfer company.
No longer side-lined as a computationally-hungry scientific curiosity, two-dimensional mass spectrometry is becoming a fully-fledged analytical technique. Dr Maria van Agthoven explains to Laboratory News how the device she and Professor Peter O'Connor have invented, in the Department of Chemistry, could make this technique widely available for the first time, leading to a revolution in the pharmacuetical and biomedical communities.
Warwick neuroscientist Professor Nick Dale talks to the Observer about the SMARTChip stroke diagnostic tool he developed, and about Sarissa Biomedical, the spin out company set up by Warwick Ventures to commercialise the technology.
Warwick Analytics, a University of Warwick spin-out, is one of just four companies selected to join a global business accelerator programme launched by International Airlines Group. The programme, called Hangar 51, aims to create new partnerships that can improve customer experience and introduce new digital technologies. Warwick Analytics, specialists in developing automated predictive analytics to detect problems in manufacturing processes, will join the Data-Driven Decisions category of the accelerator.
ARM Ltd, the world’s leading semiconductor IP company, has just purchased Warwick spin out, Allinea Software, a company developed out of high performance computing research at the University of Warwick in an £18 million pound deal.
Warwick spin out, Warwick Audio Technologies, the company that produces the revolutionary new High-Precision Electrostatic Laminate audio speaker, has appointed Gary Waters, former Vice President and General Manager of BOSE Corporation, as a Non-Executive Director.
Pharmaceutical research could be quicker and more precise, thanks to an innovative breakthrough in the analytical sciences from the University of Warwick.
Professor Peter O’Connor and Dr Maria van Agthoven in the Department of Chemistry have invented a device which makes 2D mass spectrometry - an effective process for analysing and sequencing proteins - widely accessible for the first time ever.